Furthermore, there are new imaging and therapeutic approaches to vitreomacular interface abnormalities, intraocular tumors, posterior uveitis, hereditary retinal degenerations, as well as surgical diseases of the retina. These areas of investigation are relatively new, and most ophthalmologists are not aware of the myriad of new clinical trials relevant to these diseases. Thus, these subjects are areas of great interest both to ophthalmologists who treat these diseases and to those who refer these cases for further management. Presentations were chosen to emphasize new information and consensus on the use of these biologic agents to treat the neovascular and non-neovascular forms of age-related macular degeneration, vitreomacular interface abnormalities, diabetic retinopathy, intraocular tumors, and posterior uveitis. In addition, cases were chosen highlighting new information being reported by randomized clinical trials in these disease areas.

• Recognize the role of anti-angiogenic treatments for eyes with choroidal neovascularization from age-related macular degeneration or diabetic retinopathy, including proliferative diabetic retinopathy and diabetic macular edema.
• Evaluate recent clinical studies evaluating treatments for hereditary retinal degenerations.
• Recognize the role of imaging in the management of vitreomacular interface abnormalities.
• Review the current and emerging therapeutic approaches for surgical retinal diseases.
• Summarize the evidence of surgical and medical treatments for intraocular tumors.
• Detect which patients are appropriate for biologic treatments of posterior uveitis.